Related Experiment Video

Updated: May 23, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Poly (ADP-ribose) polymerase inhibitors in cancer treatment

Kathryn A Mason1, Uma Raju, Thomas A Buchholz

  • 1Departments of *Experimental Radiation Oncology †Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX ‡Department of General Surgery, M.D. Anderson Cancer Center, Orlando, FL.

American Journal of Clinical Oncology
|April 13, 2012
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors show promise in cancer therapy by affecting DNA repair and cell survival. Preclinical data suggest PARP inhibitors synergize with radiation and chemotherapy, with initial clinical trials underway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Poly (ADP-ribose) polymerase (PARP) plays a crucial role in DNA repair and cellular functions.
  • Dysregulation of PARP activity is implicated in carcinogenesis, inflammation, and cancer therapy resistance.
  • PARP inhibitors represent a novel therapeutic strategy in oncology.

Purpose of the Study:

  • To review the biological rationale for using PARP inhibitors in cancer treatment.
  • To present preclinical data on the synergistic effects of PARP inhibitors with conventional therapies.
  • To summarize the findings from early-phase clinical trials of PARP inhibitors.

Main Methods:

  • Literature review of preclinical studies on PARP inhibitors.
  • Analysis of data from in vitro and in vivo experiments.
  • Summary of results from initial human clinical trials.

Main Results:

  • PARP inhibitors modulate critical cellular processes, including DNA repair and cell survival.
  • Preclinical studies demonstrate synergistic interactions between PARP inhibitors and radiation/chemotherapy.
  • Early clinical trials indicate potential efficacy and safety of PARP inhibitors in cancer patients.

Conclusions:

  • PARP inhibitors offer a promising approach to enhance cancer therapy.
  • The combination of PARP inhibitors with radiation and chemotherapy warrants further investigation.
  • Ongoing clinical trials will further elucidate the therapeutic potential of PARP inhibitors.

More Related Videos

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)10:05

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)

Published on: January 20, 2016

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...